Glycosylated haemoglobin and HbA1c are terms that frequently appear together in diabetes care, leading many patients and clinicians to wonder whether they mean exactly the same thing. In short, HbA1c is a specific fraction of glycated haemoglobin — the subtype routinely measured in NHS blood tests to diagnose and monitor diabetes. Understanding the distinction, how results are interpreted, what targets to aim for, and when the test may be unreliable is essential for anyone managing diabetes or at risk of developing it. This article explains everything you need to know in line with current NICE and NHS guidance.

Glycosylated Haemoglobin and HbA1c: Are They the Same Thing?

HbA1c is the specific glycated haemoglobin fraction measured in routine NHS blood tests; 'glycosylated haemoglobin' is a broader term covering all glucose-attached haemoglobin fractions, making the two terms effectively interchangeable in clinical practice.

In everyday clinical and patient-facing use, the terms 'glycosylated haemoglobin' and 'HbA1c' are often used interchangeably — and in most practical contexts they refer to the same test. However, it is worth understanding the distinction: 'glycosylated haemoglobin' (or more precisely, 'glycated haemoglobin') is a broad term describing all fractions of haemoglobin that have had glucose attached to them. HbA1c is the specific glycated fraction that is measured in routine blood tests. It is this particular subtype that is clinically relevant for diagnosing and monitoring diabetes. The spelling difference — 'hemoglobin' versus 'haemoglobin' — simply reflects American versus British English conventions.

Haemoglobin is the protein found inside red blood cells that carries oxygen around the body. When glucose circulates in the bloodstream, it naturally attaches to haemoglobin in a process called glycation. Because red blood cells have a lifespan of approximately 120 days (around three to four months), the HbA1c test provides a reliable picture of average blood glucose levels over the preceding two to three months, with the most recent four to six weeks contributing most to the result. This makes it considerably more informative than a single fasting glucose reading, which only reflects blood sugar at one point in time.

For these reasons, HbA1c is recommended by NICE and used routinely across NHS services in England, Scotland, Wales, and Northern Ireland for diagnosing type 2 diabetes and monitoring long-term glycaemic control in people already living with diabetes. It is important to note, however, that HbA1c is not appropriate for diagnosing type 1 diabetes, gestational diabetes, or diabetes in children and young people — and there are other situations where it may not give reliable results (discussed below).

How HbA1c Is Measured and What the Results Mean

HbA1c is measured via a venous blood sample in an IFCC-accredited laboratory, with UK results reported in mmol/mol; 48 mmol/mol or above indicates type 2 diabetes, and 42–47 mmol/mol indicates non-diabetic hyperglycaemia.

HbA1c is measured through a blood test, typically taken from a vein in the arm and analysed in an IFCC (International Federation of Clinical Chemistry)-aligned laboratory. In the UK, results are reported in millimoles per mole (mmol/mol), following the standardised IFCC units adopted by the NHS. You may occasionally see older results expressed as a percentage (%), which was the previous reporting convention.

It is important to note that point-of-care (finger-prick) HbA1c devices are used in some GP surgeries and clinics for monitoring purposes, but they are not recommended for making a new diagnosis of diabetes. A diagnosis should always be based on a venous blood sample analysed by an accredited laboratory using an IFCC-aligned method.

Understanding what the numbers mean:

• Below 42 mmol/mol (6.0%): Normal range — diabetes is unlikely.

• 42–47 mmol/mol (6.0–6.4%): Non-diabetic hyperglycaemia (NDH), sometimes referred to as prediabetes — an increased risk of developing type 2 diabetes.

• 48 mmol/mol (6.5%) or above: Indicative of type 2 diabetes, particularly when confirmed on a repeat test.

For a diagnosis of type 2 diabetes to be made on the basis of HbA1c alone, NICE guidance recommends a result of 48 mmol/mol or above on two separate occasions in a person without symptoms. If a person has clear symptoms of diabetes, a single result may be sufficient.

When HbA1c should not be used for diagnosis

HbA1c is not suitable for diagnosing diabetes in the following situations, as results may be unreliable or misleading:

• Symptoms have been present for fewer than two months (acute onset)

• Suspected type 1 diabetes

• Pregnancy (including suspected gestational diabetes)

• Children and young people

• Conditions that affect red blood cell turnover or haemoglobin structure (see below)

In these circumstances, alternative tests are used. For diagnosing diabetes when HbA1c is unsuitable, a fasting plasma glucose test or an oral glucose tolerance test (OGTT) is recommended, as per NICE and WHO guidance. Your GP or diabetes care team will advise on the most appropriate test for your situation.

Understanding Your HbA1c Target on the NHS

NICE recommends an HbA1c target of 48 mmol/mol for type 2 diabetes managed without hypoglycaemia risk, rising to 53 mmol/mol for those on insulin or sulphonylureas; targets are personalised to balance glycaemic control against hypoglycaemia risk.

For people already diagnosed with diabetes, HbA1c monitoring is a cornerstone of ongoing care. The NHS recommends that HbA1c is checked every three to six months until levels are stable, and then every six months thereafter. The frequency may increase if treatment is being adjusted or if glycaemic control is poor.

Target HbA1c levels vary depending on individual circumstances, treatment regimen, and the presence of other health conditions. According to NICE guidelines (NG28 for type 2 diabetes in adults):

• 48 mmol/mol (6.5%) is the general target for people managing type 2 diabetes through lifestyle changes or a single medication that does not carry a risk of hypoglycaemia.

• 53 mmol/mol (7.0%) is the target for those on medications that carry a risk of hypoglycaemia, such as sulphonylureas or insulin.

• If HbA1c rises to 58 mmol/mol (7.5%) or above despite an agreed treatment plan, NICE recommends considering treatment intensification.

• For some individuals — including older adults, those with frailty, or those where tight control poses greater risk than benefit — targets may be relaxed. The appropriate level should be agreed individually with your care team, balancing glycaemic control against the risk of hypoglycaemia and overall quality of life.

It is important to understand that HbA1c targets are personalised — a lower number is not always better for every patient. Overly aggressive glucose lowering can increase the risk of hypoglycaemia (dangerously low blood sugar), which carries its own serious health risks. Your diabetes care team will work with you to agree a realistic and safe target.

If you experience side effects that you think may be related to your diabetes medicines — including symptoms of hypoglycaemia — you can report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Factors That Can Affect HbA1c Accuracy

Haemolytic anaemia, haemoglobin variants, recent blood transfusion, iron deficiency, and advanced CKD can all cause falsely high or low HbA1c results; fasting plasma glucose, OGTT, or fructosamine may be used as alternatives.

While HbA1c is a reliable marker in most people, certain medical conditions and physiological factors can affect its accuracy, leading to results that do not accurately reflect average blood glucose levels. Healthcare professionals are trained to recognise these situations and will consider alternative tests where appropriate.

Conditions or factors that may cause unreliable HbA1c results include:

• Haemolytic anaemia — red blood cells are destroyed more rapidly than usual, shortening the time available for glycation and typically lowering HbA1c

• Recent blood transfusion — this renders HbA1c uninterpretable for approximately two to three months after the transfusion, as donor red blood cells alter the result in an unpredictable direction

• Haemoglobin variants (such as sickle cell trait, haemoglobin C disease, or other haemoglobinopathies) — depending on the laboratory assay used, these can cause falsely high or falsely low results; UK laboratories are trained to flag potential interference when variants are detected

• Iron deficiency anaemia — before treatment, this may cause falsely elevated HbA1c; as iron stores are replenished and red blood cell turnover changes, results may shift, making interpretation around the time of treatment unreliable

• Vitamin B12 or folate deficiency — may affect red blood cell production and turnover, potentially influencing results

• Advanced chronic kidney disease (CKD) — HbA1c may be unreliable in advanced CKD; shortened red blood cell survival and the use of erythropoiesis-stimulating agents (ESAs) often lower HbA1c, but the direction and degree of effect varies by individual and assay

• Splenectomy (removal of the spleen) — prolongs red blood cell lifespan, which may cause falsely elevated results

• Pregnancy (particularly the second and third trimesters) — physiological changes affect red blood cell turnover

• Other factors — significant recent blood loss or reticulocytosis, certain medicines (such as dapsone), high-dose vitamin C or E supplementation, severe hypertriglyceridaemia, and liver disease may also affect results

HbA1c measurement in the UK follows IFCC and NGSP standardisation, with laboratory practice guided by the Royal College of Pathologists (RCPath) and the Association for Clinical Biochemistry and Laboratory Medicine (ACB). Local laboratories will flag results where haemoglobin variants or other interferences are detected.

When HbA1c is unreliable, alternatives include:

• Fasting plasma glucose or oral glucose tolerance test (OGTT) — for diagnostic purposes

• Capillary blood glucose self-monitoring (SMBG) or continuous glucose monitoring (CGM) — for ongoing monitoring, particularly in type 1 diabetes

• Fructosamine or glycated albumin — which reflect glucose control over a shorter period (approximately two to three weeks) and may be used when HbA1c is not interpretable

Your GP or diabetes care team will advise on the most appropriate alternative if your HbA1c result is thought to be unreliable.

When to Speak to Your GP About Your HbA1c Levels

Speak to your GP if your HbA1c is 42 mmol/mol or above, has risen significantly, or if you have symptoms of poor glycaemic control; seek same-day emergency help if symptoms suggest type 1 diabetes or diabetic ketoacidosis.

Knowing when to seek medical advice about your HbA1c is an important part of managing your health proactively. Whether you have been newly diagnosed, are in the non-diabetic hyperglycaemia range, or are already on treatment, there are several situations where contacting your GP or diabetes care team is advisable.

You should speak to your GP if:

• Your HbA1c result comes back at 42 mmol/mol or above and you have not previously been told you are at risk of diabetes

• Your HbA1c has risen significantly since your last test, even if it remains within your target range

• You are experiencing symptoms such as increased thirst, frequent urination, unexplained weight loss, or persistent fatigue, which may suggest poor glycaemic control

• You are concerned about hypoglycaemia (symptoms include shakiness, sweating, confusion, or palpitations), particularly if you are on insulin or a sulphonylurea — you can also report suspected medicine side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk

• You are pregnant or planning a pregnancy, as glucose targets and monitoring requirements differ significantly during this period; gestational diabetes is diagnosed using glucose tests (not HbA1c) per NICE guideline NG3, and care should be led by your midwife and diabetes team

• You have been told your HbA1c result may be unreliable due to a haemoglobin variant or other medical condition

Seek same-day or emergency medical help if you or someone you know develops symptoms that may suggest type 1 diabetes or diabetic ketoacidosis (DKA) — including rapidly worsening thirst, very frequent urination, significant unintentional weight loss, abdominal pain, vomiting, drowsiness, or a fruity smell on the breath. These symptoms require urgent assessment and HbA1c alone is not used to diagnose type 1 diabetes.

Not sure if this is normal? Chat with one of our pharmacists →

It is equally important not to wait for your annual review if something does not feel right. The NHS Long Term Plan emphasises early intervention in diabetes care to prevent complications such as cardiovascular disease, kidney damage, neuropathy, and retinopathy. Your GP, practice nurse, or diabetes specialist nurse can review your results, adjust your treatment plan, and refer you to specialist services if needed. Open, regular communication with your care team is one of the most effective tools for maintaining good long-term health.

Frequently Asked Questions